CYP2D6-mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528

Drug Metabolism and Disposition

Volumn 36, Issue 3, 2008, Pages 529-534

  Kotsuma, Masakatsu ^a   Tokui, Taro ^a   Ishizuka Ozeki, Tomoko ^a   Honda, Tomoyo ^a   Iwabuchi, Haruo ^a   Murai, Takahiro ^a   Ikeda, Toshihiko ^a   Saji, Hideo ^b  

^a DAIICHI SANKYO CO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A; ASPARTIC ACID; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DRUG METABOLITE; FATTY ACID; GLUTAMIC ACID; NITROGEN; O DEMETHYLASE; PACTIMIBE; R 125528; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FATTY ACID OMEGA OXIDATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC CIRCULATION;

ACETYL-COA C-ACYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; INDOLEACETIC ACIDS; KINETICS; LYMPHOCYTES; MICROSOMES, LIVER;

EID: 40849111644     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018853     Document Type: Article

References (34)

1. Brynne N, Dalen P, Alvan G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 63:529-539.
2. CDER (2005) Guidance for Industry - Safety Testing of Drug Metabolites, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC.
3. de Groot MJ, Ackland MJ, Horne VA, Alex AA, and Jones BC (1999a) Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:1515-1524.
4. de Groot MJ, Ackland MJ, Horne VA, Alex AA, and Jones BC (1999b) A novel approach to predicting P450 mediated drug metabolism: CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:4062-4070.
5. Ekins S, Berbaum J, and Harrison RK (2003) Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. Drug Metab Dispos 31:1077-1080.
6. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg MJ, Lennard MS, Tucker GT, et al. (1995) Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 270:29055-29058.
7. Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, and Kivisto KT (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78:378-387.
8. Gibbs JP, Hyland R, and Youdim K (2006) Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab Dispos 34:1516-1522.
9. Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, et al. (2002) Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41:11025-11034.
10. Hainer JW, Terry JG, Connell JM, Zyruk H, Jenkins RM, Shand DL, Gillies PJ, Livak KJ, Hunt TL and Crouse JR 3rd (1994) Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther 56:65-74.
11. Harris WS, Dujovne CA, von Bergmann K, Neal J, Akester J, Windsor SL, Greene D, and Look Z (1990) Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther 48:189-194.
12. Ishi M, Tomono Y, Sanma H, Yamoto C, Sekino H, Nomura M, and Nakaya N (1994) Pharmacokinetics of novel ACAT inhibitor E5324, in healthy volunteers (Abstract). Atherosclerosis 109:283.
13. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
14. Kashiwa M, Masuyama Y, Miyauchi H, Uchida T, Naganuma S, Kakuta H, Terada M, Kiriyama T, Matsuda K, Ito N, et al. (1997) Pharmacological properties of YM17E, an acyl-CoA: cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol 73:41-50.
15. Kitayama K, Koga T, Inaba T, and Fujioka T (2006a) Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor. Eur J Pharmacol 543:123-132.
16. Kitayama K, Koga T, Maeda N, Inaba T, and Fujioka T (2006b) Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits. Eur J Pharmacol 539:81-88.
17. Kitayama K, Tanimoto T, Koga T, Terasaka N, Fujioka T, and Inaba T (2006c) Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur J Pharmacol 540:121-130.
18. Matsuo M, Hashimoto M, Suzuki J, Iwanami K, Tomoi M, and Shimomura K (1996) Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA: cholesterol acyltransferase inhibitor, FR145237. Toxicol Appl Pharmacol 140:387-392.
19. Molden E, Johansen PW, Boe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, and Lehne G (2002) Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 72:333-342.
20. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, and Tokui T (2004) Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 93:847-854.
21. Nakaya N, Nakamichi N, Sekino H, Nomura M, Ishii M, Tomono Y, and Yamato C (1994) Effect of a novel ACAT inhibitor, E5324, on serum lipids and lipoproteins in healthy volunteers (Abstract). Atherosclerosis 109:284.
22. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, et al. (2006) Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354:1253-1263.
23. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, and Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027.
24. Peck RW, Wiggs R, and Posner J (1995) The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an acylCoA:cholesterol acyl transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Eur J Clin Pharmacol 49:243-249.
25. Reindel JF, Dominick MA, Bocan TM, Gough AW, and McGuire EJ (1994) Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys. Toxicol Pathol 22:510-518.
26. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
27. Schmid B, Bircher J, Preisig R, and Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624.
28. Strobl GR, von Kruedener S, Stockigt J, Guengerich FP, and Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 36:1136-1145.
29. Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, et al. (2004) Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110:3372-3377.
30. Terasaka N, Miyazaki A, Kasanuki N, Ito K, Ubukata N, Koieyama T, Kitayama K, Tanimoto T, Maeda N, and Inaba T (2007) ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis 190:239-247.
31. van der Weide J and Steijns LS (1999) Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 36(Pt 6):722-729.
32. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
33. Vernetti LA, MacDonald JR, Wolfgang GH, Dominick MA, and Pegg DG (1993) ATP depletion is associated with cytotoxicity of a novel lipid regulator in guinea pig adrenocortical cells. Toxicol Appl Pharmacol 118:30-38.
34. Waxman DJ, Attisano C, Guengerich FP, and Lapenson DP (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263:424-436.